HCMSG - Hepatitis C Mentor & Support Group, Inc.
Search
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
  • Resources
    • Corona Virus
    • Hep C Facts & Stats
    • Medications and Treatments >
      • Patient Assistance Programs
    • Reading
    • Links
  • Programs/Training
    • The Circle Model >
      • THE CIRCLE Registration
      • Group and Facilitator Guide
    • Hepatitis C Online Training
    • The Hepatitis C Education and Support Group Assistance Program
    • Healthcare Provider Training
  • Newsletter
  • Blog
  • Support Us
    • Holiday 2020
  • Contact Us

PROS AND CONS OF NEW HEPATITIS C TREATMENTS

4/20/2015

4 Comments

 
  • Everyday Health
  • By Anne Harding                       Reviewed by Matthew Vorsanger, MD          

  • The FDA has approved several new cures for hepatitis C, but the drugs are so costly, some insurers will only cover them for the sickest patients.

    Hepatitis C treatment is getting faster, simpler, and more effective.  Patients on the new hepatitis C medication, Harvoni, need only pop one pill per day. Some can be cured in as little as eight weeks. And patients who take Viekira Pak, a new combination pill, for 12 to 24 weeks, don't need an added injection. This is a huge difference from just a few years ago, when hepatitis C patients had to take ribavirin pills and interferon injections for almost a year, and most weren't cured.

    “Harvoni is very easy to take, it doesn't have any significant side effects,” says David Bernstein, MD, chief of hepatology for the North Shore LIJ Health System in Manhasset, N.Y. “The only thing that you see is some patients get an occasional mild headache, which is easily treatable with aspirin or Tylenol.”

    Prior interferon-containing combo treatments had side effects that included anemia, depression, and flu-like symptoms among others.

    Here's the problem: The newer hepatitis C drugs are super-expensive. Harvoni rings in at $1,125 per pill, or $94,500 for a 12-week course of treatment, and other new medications are nearly as pricey. Insurers are scrambling to figure out how to pay for treatment without breaking the bank. Many say they will only cover costly therapies for the sickest patients. In comparison, the cost 11 out of 12 cancer drugs the FDA approved in 2012 for cancer chemotherapy was over $100,000 for a one-year treatment course. 

    “Really curing hepatitis C is now within reach for a majority of the patients that we see,” says Andrew Aronsohn, MD, an assistant professor of medicine at The University of Chicago Medicine and an expert on hepatitis treatment. “The big issue revolves around cost and access to care.” 

    Several other new hepatitis C treatments are awaiting FDA approval. “The hope is that with lots of competition and more drugs out there, the price will go down,” says Dr. Aronsohn. “That's certainly what we're hoping for.” A potential problem with using the new drugs is how to know which will be best for an individual patient, when compared to other new treatments.

    Hepatitis C TreatmentsHere's a rundown of US Food and Drug Administration-approved treatments for hepatitis C, from newest to oldest. 

    Viekira Pak: Approved December 2014. Viekira Pak is an interferon-free, all oral cure for hepatitis C for patients who have genotype 1 infections, including those with cirrhosis. The combination is ombitasvir, paritaprevir, and ritonavir pills, combined with dasabuvir pills. It is sometimes used with ribavirin. Patients take the drug for 12 to 24 weeks, and it cures over 95 percent.

    Harvoni: Approved October 2014. Harvoni is a combination of sofosbuvir (Sovaldi) and ledipasvir. The drug cured more than 90 percent of patients with hepatitis C type 1, the most common form in the United States, after 12 weeks of treatment. Some patients who have not taken antiviral drugs before can be cured in eight weeks. “It's quite a transformative medication,” Dr. Bernstein says.

    Sovaldi: Approved December 2013. Sovaldi is also a once-a-day pill, taken in combination with ribavirin or interferon. A course of treatment lasts 12 weeks, versus 24 to 48 weeks for older treatments. Some doctors have been prescribing an off-label combination (meaning not specifically FDA-approved) of Sovaldi with Olysio (simeprevir) to avoid side effects associated with the older drugs. The two-drug combo costs roughly $150,000 for a course of treatment. Patients with hepatitis C genotype 2 and genotype 3 are currently treated with a combo of Sovaldi and ribavirin, while patients with genotype 4 — who are very rare in the United States — must still be treated with interferon and ribavirin.

    Olysio (simeprevir): Approved November 2013. Olysio is a once-a-day pill and, like Sovaldi, approved for use in combination with interferon and ribavirin. It is approved for treating hepatitis C genotype 1. The drug combination cured 80 percent of those with hepatitis C in 24 weeks, including patients who failed earlier drug treatments.

    Telaprevir (Incivek/)/Boceprevir (Victrelis): Approved May 2011. Telaprevir and boceprevir were the first new treatments available for hepatitis C in 20 years. These drugs were also the first to directly attack the hepatitis C virus. Both are protease inhibitors, and prevent the virus from making copies of itself. Either must be taken along with ribavirin and interferon, but the course of treatment for the triple combo takes 24 weeks, versus 48 weeks for the interferon/ribavirin only regimen. Cure rates are about 80 percent with the telaprevir-based combo, while the boceprevir-based combo cures about two-thirds of patients.

    Issues in curing hepatitis C today are cost and access to care.

    Ribavirin: Approved in 1998. Patients take this oral medication twice a daily, and it must be used in combination with interferon. Side effects include a serious form of anemia that can make heart disease worse and lead to a heart attack. A course of interferon/ribavirin therapy lasts 48 weeks, and will cure about 40 percent to 45 percent of patients.



    Interferon: Approved in 1991. Interferon is a human-made copy of an infection-fighting substance produced by immune-system cells. Patients must take it by once-weekly injection. Side effects can be severe, and include depression, irritability, flu-like symptoms, and blood abnormalities. When the drug was used on its own to treat hepatitis C, patients had to take it for 12 to 18 months. This lengthy treatment cleared the virus in just 20 percent of patients.

    patients.http://www.everydayhealth.com/news/pros-cons-new-hepatitis-treatments-patients/



  • 4 Comments
    Libby
    4/25/2015 10:00:46 pm

    As you said above, very effective for large percentage of people , but difficult to treat population of patients have to use newer drugs and the cost is very high. Insurance balks at treating those have have been either null responders, relapsers, or a mixture of both(due to several treatments). This is particularly true for a non-cirrhotic, patient who relapsed on Sovaldi and also was a null responder to Telaprevir, Interferon, Ribavirin, etc.

    Reply
    buy custom essays link
    6/30/2015 10:37:30 pm

    It was interesting to know about merits and demerits of new hepatitis treatments. Thank you!

    Reply
    but custom essays link
    7/28/2015 08:59:29 pm

    Thanks for such an informative article! It was a good idea to analyze all those new approaches to treat hepatitis C.

    Reply
    buy custom essays link
    7/28/2015 09:00:49 pm

    It was a good idea to analyze all those new approaches to treat hepatitis C. Thanks!

    Reply

    Your comment will be posted after it is approved.


    Leave a Reply.

      Archives

      January 2021
      December 2020
      November 2020
      October 2020
      September 2020
      August 2020
      July 2020
      June 2020
      May 2020
      April 2020
      March 2020
      February 2020
      January 2020
      December 2019
      November 2019
      October 2019
      August 2019
      July 2019
      June 2019
      May 2019
      April 2019
      March 2019
      February 2019
      January 2019
      December 2018
      November 2018
      October 2018
      September 2018
      August 2018
      July 2018
      June 2018
      May 2018
      April 2018
      March 2018
      February 2018
      January 2018
      December 2017
      November 2017
      October 2017
      September 2017
      August 2017
      July 2017
      June 2017
      May 2017
      April 2017
      March 2017
      February 2017
      January 2017
      December 2016
      November 2016
      October 2016
      September 2016
      August 2016
      July 2016
      June 2016
      May 2016
      April 2016
      March 2016
      February 2016
      January 2016
      December 2015
      November 2015
      October 2015
      September 2015
      August 2015
      July 2015
      June 2015
      May 2015
      April 2015
      March 2015
      February 2015
      January 2015
      December 2014
      November 2014
      October 2014
      September 2014
      August 2014
      July 2014
      June 2014
      May 2014
      April 2014
      March 2014
      February 2014
      January 2014
      December 2013
      November 2013
      October 2013
      September 2013
      August 2013
      July 2013
      June 2013
      May 2013
      April 2013
      March 2013
      February 2013
      January 2013
      December 2012
      November 2012
      October 2012
      September 2012
      August 2012
      July 2012
      June 2012
      May 2012
      April 2012
      March 2012
      February 2012
      January 2012
      December 2011
      November 2011
      October 2011
      September 2011
      August 2011
      July 2011
      June 2011
      May 2011

      Categories

      All

      RSS Feed

    Privacy Policy